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The functional reach (FR) test as a complex measure of balance including limits of stabil-
ity has been proven to differentiate between patients with Parkinson’s disease (PD) and
controls (CO). Recently, it has been shown that the instrumentation of the FR (iFR) with a
wearable sensor may increase this diagnostic accuracy. This cross-sectional study aimed
at investigating whether the iFR has the potential to differentiate individuals with high risk
for PD (HRPD) from CO, as the delineation of such individuals would allow for, e.g., early
neuromodulation. Thirteen PD patients, 13 CO, and 31 HRPD were investigated. HRPD
was defined by presence of an enlarged area of hyperechogenicity in the mesencephalon
on transcranial sonography and either one motor sign or two risk and prodromal markers
of PD. All participants were asked to reach with their right arm forward as far as possible
and hold this position for 10 s. During this period, sway parameters were assessed with an
accelerometer (Dynaport, McRoberts) worn at the lower back. Extracted parameters that
differed significantly between PD patients and CO in our cohort [FR distance (shorter in
PD), anterior–posterior and mediolateral acceleration (both lower in PD)] as well as JERK,
which has been shown to differentiate HRPD from CO and PD in a previous study, were
included in a model, which was then used to differentiate HRPD from CO. The model
yielded an area under the curve of 0.77, with a specificity of 85%, and a sensitivity of 74%.
These results suggest that the iFR can contribute to an assessment panel focusing on the
definition of HRPD individuals.
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INTRODUCTION
There is a great need for biomarkers in the prodromal phase of
Parkinson’s disease (PD) because valid definitions of this phase,
and its progression would open entirely new opportunities for
treatment and even prevention of neurodegeneration (Postuma
et al., 2012a; Berg and Bandmann, 2013; Wang et al., 2013; Lerche
et al., 2014). Motor parameters seem to be particularly promis-
ing for this purpose as subtle motor changes in individuals at
high risk for PD (HRPD) may occur several years before clinical
diagnosis can be made. This has been shown for distal (Gaenslen
et al., 2011; Postuma et al., 2012b) as well as for axial motor
symptoms such as gait and balance (Mirelman et al., 2011; Maet-
zler and Hausdorff, 2012; Maetzler et al., 2012). Particularly, the
latter studies (Mirelman et al., 2011; Maetzler et al., 2012) indi-
cated that challenging test situations may be more effective in
delineating subtle motor deficits in this prodromal phase, than
do non-challenging test situations. More specifically, we could
recently demonstrate that HRPD individuals show, under chal-
lenging static balance conditions, a higher variability of trunk
acceleration and a lower smoothness of sway (indicated by higher
JERKs) in both anterior–posterior (AP) and mediolateral (ML)
direction, compared to both controls (CO) and PD.
The limit of stability is a dimension of the postural control
system, which reflects the maximum displacement of the body’s
center of mass over a fixed base of support of the feet without losing
balance (Horak et al., 2005). The functional reach (FR) test enables
to determine this limit of stability in the AP direction, by reach-
ing forward during quiet standing (Duncan et al., 1990). A good
and practical definition of the FR is the greatest distance in any
direction a person can reach out from a midline verticale position
without falling or stepping. Thus, the FR is an operationalization
of “the self-perceived limits of stability” (Mancini et al., 2008). The
FR has been shown to differentiate older fallers from non-fallers
(Duncan et al., 1992; Huang et al., 1998; Almeida et al., 2012), and
the FR distance is a useful outcome parameter for fall prevention
programs and progressive strength training (Sousa and Sampaio,
2005; Lin et al., 2007). Importantly, the test has also been shown to
discriminate between PD patients and CO. One study (Smithson
et al., 1998) found that PD patients have a shorter FR distance
(~4 cm) than CO, which has been confirmed by another study
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(Mancini et al., 2008). Recently, first data about an instrumented
FR (iFR) using a wearable sensor during the task have been pre-
sented (Cattabriga et al., 2013). The data indicate that the approach
is feasible, and may improve diagnostic accuracy of PD.
Comparing HRPD individuals with PD patients has its weak-
nesses, in particular, in experiments that test dysfunction and
compensation mechanisms in parallel, and these mechanisms
are difficult to disentangle. A particular strength of the analysis
of an iFR can be the consideration of two components: dis-
tance (how far someone can reach) and behavior (how does
someone “behave” at her/his self-perceived limit). The further a
study participant reaches due to motivation issues (sensorimo-
tor integration), the better is the distance value but the worse
are the sway parameters, and vice versa. Moreover, we included
the parameters shown previously to be different in HRPD and
CO (Maetzler et al., 2012) in our model, especially because pre-
vious data suggests a U -shaped progress of some parameters
from CO over HRPD, to PD. A U -shaped process can contain
compensatory and/or adaptation mechanism, as well as hidden
pathophysiological aspects.
To our knowledge, there is no study available yet on changes of
stability limits in prodromal PD. As already stated, subtle motor
changes can be detected with quantitative assessment tools before
the clinical diagnosis can be made (Yang et al., 2008; Mirelman
et al., 2011; Maetzler and Hausdorff, 2012; Maetzler et al., 2012).
Limits of stability are reduced in PD (Rossi et al., 2009; Menant
et al., 2011) and can be found even in early untreated disease stages
(Mancini et al., 2012). Thus, we were interested whether we could
detect differences between PD and CO in challenging limits of
stability paradigm (Duncan et al., 1990; Kamata et al., 2007).
Moreover, based on these assumptions and our previous results
we were interested in the potential of the iFR to differentiate
between HRPD individuals and CO.
MATERIALS AND METHODS
ETHICS
The ethical committee of the Medical Faculty of Tuebingen
approved the study protocol and written informed consent was
sought from all participants (Liepelt-Scarfone et al., 2013).
INDIVIDUALS
In this cross-sectional study, 13 PD patients, 13 CO, and 31 HRPD
individuals were included. The study presented here is part of the
observational PMMP study on HRPD individuals, for details we
refer to Maetzler et al. (2012), Liepelt-Scarfone et al. (2013), Louter
et al. (2014). In brief, PMMP stands for “progression markers in
the premotor phase” of PD, which is a prospective longitudinal
2-year study. The aim of the study is to monitor the progression
of the disease until the development of (subtle) motor changes in
older adults with risk factors for PD. All HRPD had an enlarged
area of hyperechogenicity of the substantia nigra on transcra-
nial sonography (>0.19 cm2 on at least one side). The enlarged
area of hyperechogenicity in the mesencephalon is one of the
most relevant risk factors for future PD in individuals older than
50 years (Berg et al., 2011). Additionally, either one cardinal motor
sign of PD (slight bradykinesia, rigidity, tremor, postural instabil-
ity) assessed by the unified Parkinson disease rating scale motor
Table 1 | Demographics and clinical parameters.
PD (N =13) Co (N =13) HRPD (N =31) p-value
Age (years) 65.0 (9.4) 63.9 (7.3) 62.6 (5.0) 0.53
Male sex (%) 8 (62) 7 (54) 23 (74) 0.38
Height (m) 1.73 (0.08) 1.71 (0.09) 1.74 (0.06) 0.64
Weight (kg) 77 (11) 72 (6) 78 (12) 0.23
BMI (kg/m2) 25.6 (2.8) 24.6 (1.9) 25.8 (3.2) 0.44
MMSE (0–30) 29.3 (0.9) 29.7 (0.5) 29.1 (0.8) 0.10
BDI (0–63) 9.6 (8.3) 2.9 (3.6)* 5.7 (4.8) 0.01
UPDRS-III (0–129) 26.8 (11.0) 0.2 (0.6)* 3.0 (3.0)*,# <0.0001
SN+ (cm2) 0.24 (0.04) 0.12 (0.03)* 0.26 (0.05)*,# <0.0001
Age at disease
onset (years)
60.5 (8.9)
Disease
duration (years)
4.5 (2.8)
Data are presented with the mean and SD, or with frequency. p-values were
assessed using ANOVA with post hoc Student’s t-test or with the Pearson Chi
square test.
BDI, Beck’s depression inventory; BMI, body mass index; Co, controls; HRPD,
individuals at high risk for future Parkinson’s disease (PD); MMSE, mini-mental
state examination; SN+, hyperechogenicity of the mesencephalic region includ-
ing the substantia nigra; UPDRS-III, motor part of the unified Parkinson disease
rating scale.
*p<0.017 compared to PD.
#p<0.017 compared to controls (Co).
part (UPDRS-III), or two of a set of well-established risk and
prodromal markers: positive family history, one-sided reduced
arm swing, history of depression, and hyposmia (<75% correct
answers in the identification test of the Sniffin’ Sticks) have to be
present. PD diagnosis was excluded for HRPD and CO by clinical
investigation. We decided to include individuals with a combi-
nation of markers as the accumulation of risk/prodromal factors
in an individual increases the risk of getting PD at least linearly
(Liepelt et al., 2011; Ross et al., 2012; Siderowf et al., 2012). Demo-
graphics and clinical characteristics are illustrated for the three
groups (Table 1).
FUNCTIONAL REACH TEST AND EXTRACTION OF QUANTITATIVE DATA
All participants stood upright in narrow stance, the right arm
reaching out without bending forward. The start and end positions
were assessed with a metal rod, which was movable and included
a tapeline. The participants were instructed to touch a small plate
at the end of the rod with their right fingertip, to push the plate
forward as far as possible, and then to hold this position for 10 s
without performing a compensation step (Figure 1). Then the par-
ticipants moved back to the initial position. The FR distance was
measured in centimeters. During the assessment, all study partici-
pants wore an accelerometer (Dynaport Hybrid®, McRoberts, The
Hague, The Netherlands) at the lower back.
Only sensor data from the maximal forward reach phase – in
which individuals had to hold the determined position – were
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FIGURE 1 | Performance of the instrumented functional reach test (SEH). Participants were asked to stand upright (A), reach forward as far as possible by
pushing the rod, and then to hold the position for 10 s (B). The sensor was worn at the lower back (arrow).
extracted and analyzed. We did not quantify the transition phase,
which has previously also been shown to be associated with fall
risk (Cattabriga et al., 2013).
STATISTICS
Statistical analyses were performed with JMP 10.0, SAS. Demo-
graphic and clinical data are presented with mean and SD, or
with frequency. p-Values were calculated using Student’s t -test,
ANOVA, or Pearson’s Chi square test (Table 1). Quantitative
FR parameters were compared between PD patients and CO
using Student’s t -test after testing for normal distribution. Non-
normally distributed parameters (JERK AP and ML) were log-
transformed before analysis. Parameters that reached a p-value
below 0.05 were included in a logistic regression model. Sensitivity
and specificity in differentiating HRPD to CO was calculated by
ROC-analysis. The additional value of inclusion of parameters was
confirmed by an increase of r2 (Table 3). Second, another regres-
sion model was calculated, which additionally included JERK in
the AP and ML direction. These parameters have been shown
to differentiate HRPD from CO and PD in a U -shaped manner
(Maetzler et al., 2012), and may thus be overlooked by the above
explorative model, which assumes linear changes of parameters in
the disease course.
RESULTS
CHARACTERISTICS OF THE COHORTS
Differences in age, gender, weight, height, and MMSE score did
not reach significance among the investigated cohorts (Table 1).
PD patients had significantly higher UPDRS and BDI (p< 0.017)
scores, indicating more severe motor problems and depressive
symptoms, than both CO and HRPD. Probably due to the inclu-
sion criteria (see above), CO had lower UPDRS values than HRPD
individuals. Both PD and HRPD individuals had comparable
echogenicity of the substantia nigra (SN+) values, which were
both, as a mean, significantly larger than those of CO (p< 0.017,
Table 1).
QUANTITATIVE FR ANALYSIS BETWEEN PD PATIENTS AND CONTROLS
All individuals were able to perform the trial correctly within the
first trial. PD patients differed from CO in the following parame-
ters: FR distance (p= 0.03), AP acceleration (p= 0.04), and ML
acceleration (p= 0.03, Figure 2). No significant differences could
be detected for the following parameters: area of sway, velocity
(AP and ML), JERK (AP and ML), and mean power frequency
(p> 0.05, Table 2).
MODEL-BASED APPROACH TO DIFFERENTIATE HRPD FROM CONTROLS
The three above-mentioned parameters that differed significantly
between PD patients and CO were included in a model to test their
utility to differentiate HRPD from CO. The inclusion of these para-
meters yielded an AUC of 0.70, with a specificity of 70%, and a
sensitivity of 77%. The additional inclusion of the JERK parame-
ters in the AP and ML direction improved the AUC to 0.77 and the
specificity to 85%, without relevantly affecting sensitivity (74%).
AUC as well as specificity and sensitivity values of different models
were calculated (Table 3).
DISCUSSION
The main finding of this study is that a combination of mark-
ers extracted out of an iFR assessment differentiates HRPD from
CO with fair accuracy, sensitivity, and specificity. Our observa-
tions basically confirm findings from previous studies investigat-
ing (subtle) motor deficits in HRPD individuals (Gaenslen et al.,
2011; Mirelman et al., 2011; Maetzler and Hausdorff, 2012; Maet-
zler et al., 2012; Postuma et al., 2012a). The results support the idea
that challenging motor tasks may have a particularly high potential
to discover those individuals who eventually convert to PD.
The three parameters of the iFR, which separated PD from CO
and also reached a satisfactory discrimination between HRPD and
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FIGURE 2 | Parameters included in the model for the differentiation of controls from individuals with high risk for Parkinson’s disease (A), which
yielded an area under the curve (AUC) of 0.77, with a specificity of 85%, and a sensitivity of 74% (B). AP, anterior–posterior.
Table 2 | Quantitative functional reach (FR) parameters of patients
with Parkinson’s disease (PD), controls (Co), and individuals with high
risk for PD (HRPD).
PD (N =13) Co (N =13) p-Value HRPD (N =31)
FR distance (cm) 24.6 (4.6) 30.7 (5.87) 0.03 29.3 (6.1)
Sway area (mm2) 20.3 (36.8) 14.5 (13.5) 0.50 10.3 (14.6)
Velocity
AP (mm/s)
21.8 (30.3) 18.9 (14.6) 0.78 25.0 (21.3)
Velocity
ML (mm/s)
22.4 (24.7) 17.2 (12.8) 0.50 17.6 (17.0)
Acceleration
AP (mG)
455 (189) 582 (146) 0.04 627 (169)
Acceleration
ML (mG)
37 (19) 66 (39) 0.02 55 (43)
JERK AP (mG/s) 4.6 (6.3) 4.5 (4.2) 0.97 18.1 (40.2)
JERK ML (mG/s) 9.4 (12.7) 5.8 (7.0) 0.38 9.9 (11.0)
MPF (Hz) 6.1 (0.5) 5.5 (0.5) 0.40 6.0 (0.3)
Data are presented with mean (SD). Values of PD patients and controls were
compared using Student’s t-test. HRPD values are only included here for compar-
ison purposes. Note the high JERK values in particular in the AP direction of the
HRPD individuals, compared to PD and controls. The relevant parameters for the
model are marked bold.
AP, anterior–posterior; FR, functional reach; ML, mediolateral; MPF, mean power
frequency.
CO, fit well with the currently existing biomechanical picture(s)
of PD. As discussed in the Section “Introduction” (Smithson
et al., 1998; Mancini et al., 2008) and also shown in this study,
Table 3 | Area under the curve (AUC), sensitivity, and specificity, as
well as r2 of combinations of parameters, which have been found to
be significantly different between patients with Parkinson’s disease
(PD) and controls, and which have previously shown to be altered in
individuals with high risk for future PD (HRPD) (Maetzler et al., 2012),
for the discrimination of HRPD from controls.
AUC Sensitivity (%) Specificity (%) r2 (%)
FR 0.51 41 75 0.6
A AP 0.56 55 66 1
A ML 0.61 70 58 1
FR+A AP 0.60 77 66 3
FR+A ML 0.63 51 83 3
FR+ A AP+A ML 0.70 77 70 5
JERK AP 0.61 48 85 3
JERK ML 0.61 48 86 3
A AP+A ML+ JERK
AP+ JERK ML
0.63 35 93 4
FR+A AP+A ML+
JERK AP+ JERK ML
0.77 74 85 10
A AP, acceleration in anterior–posterior direction; A ML, acceleration in mediolat-
eral direction; FR, functional reach.
PD patients yielded shorter FR distances than did age-matched
CO. This is in agreement with the previously described reduced
maximum balance range of PD patients detectable even in early
PD stages (Horak et al., 2005; Menant et al., 2011). The reduced
mean AP and ML accelerations observed during the FR in PD
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patients compared to CO may be best explained by the following
symptoms/reasons. First, PD patients suffer from an increased
muscle tone and hypokinesia, leading to reduced compensatory
motor response. Second, reduced acceleration in the AP direction
of the PD patients compared to CO may also be due to a differ-
ence of general sway strategy. Healthy older adults prefer an ankle
strategy, which mainly influences parameters in the AP direction
(Runge et al., 1999; Horak et al., 2005; Colnat-Coulbois et al.,
2011), whereas PD patients rather prefer a hip strategy, which has
lower influence on AP parameters (Horak et al., 2005). Moreover,
the reduced AP acceleration observed in the PD patients may – at
least partly – be explained by the known undershooting of reaching
to targets typically associated with PD (Demirci et al., 1997).
We found that a panel of parameters of the iFR separated
HRPD better from CO than any single parameter. This obser-
vation suggests that not a single parameter but rather a network
including a number of associated parameters is affected in the
HRPD individuals (Maetzler et al., 2013). From a “biomarker”
point of view, the consideration of a panel of parameters rather
than a single parameter within a network may increase the useful-
ness of a model to delineate individuals of interest. This has been
suggested and investigated in studies differentiating PD from CO
using biomechanical (van der Kooij et al., 2007; Zijlstra et al., 2012;
Maetzler et al., 2013; Schoneburg et al., 2013) and biochemical
approaches (Bogdanov et al., 2008; Morgan et al., 2010; Farooqui
and Farooqui, 2011; Shi et al., 2011; Mielke et al., 2013; Reeve
et al., 2013; Subramaniam and Chesselet, 2013; Mielke and Maet-
zler, 2014; Park et al., 2014). The most-often mentioned advantage
of such model-based approaches is the consideration of com-
pensation mechanisms, which certainly play an important role
in chronic and progressive diseases such as PD (Maetzler et al.,
2013). In our particular situation investigating HRPD individuals
with a motivation-dependent task, the model-based approach has
an additional advantage: this approach can account for different
strategies to perform the task. For example, if a HRPD individ-
ual is highly motivated and choses to reach as far as possible, the
FR distance may be control-like, however, correction mechanisms
will be maximally challenged. This will be reflected by changes in
the acceleration (and JERK) parameters included in the model. If
the individual decides to take a low risk to fail, the FR distance
will be PD-like, however, the acceleration parameters will not be
specifically altered. In this particular study, a model considering
the parameters relevant for such a scenario enabled us to approach
a very good specificity.
A further important observation of this study is that considera-
tion of U -shaped progress of certain balance parameters as previ-
ously suggested for a static balance paradigm (Maetzler et al., 2012)
increases the accuracy to differentiate HRPD individuals from CO
also when testing the limit of stability (i.e., JERK parameters, see
Figure 2). Ultimately, by combining quantitative FR parameters,
which show either a linear, or a non-linear U -shaped or inversed
change from normal to PD, our model yielded a fair accuracy,
specificity, and sensitivity to differentiate HRPD from CO.
The study faces some limitations. First, it used a cross-sectional
design and did not (yet) validate its findings by inclusion of PD
converters. A further limitation of the method is that, although
AUC values are fair in differentiating HRPD from CO, the
combination of parameters from the iFR explain only a minority
of the difference between the groups (Table 3).
However, we follow the study participants longitudinally and
will thus have the opportunity to test our results in the future. We
feel that these cross-sectional data are still an important contri-
bution to the field, because they may justify the inclusion of this
relatively simple task in ongoing studies on prodromal PD. Sec-
ond, as no perfect definition of HRPD individuals exist to date,
it is probable that not all of our HRPD will eventually develop
PD. However, our inclusion criteria considered the increasing risk
with increasing numbers of risk and prodromal factors (Liepelt
et al., 2011; Ross et al., 2012; Siderowf et al., 2012), which is most
probably one of the best models for the definition of such a cohort
currently available. Third, it is not fully investigated yet to which
extent the reduced limits of stability in PD are rather a compen-
satory mechanism (Demirci et al., 1997; Maetzler et al., 2013) or
have an underlying pathophysiology related to postural instabil-
ity (van Wegen et al., 2001; Błaszczyk et al., 2007; Mancini et al.,
2012; Schoneburg et al., 2013). It could be that the underlying
mechanisms of degeneration and compensation are different in
HRPD and PD. However, “clinical PD” must be considered as the
best endpoint for investigations of prodromal PD phases currently
available (Siderowf and Stern, 2008; Gaenslen et al., 2011; Berg
and Bandmann, 2013; Berg et al., 2013). Moreover, as changes
in the prodromal, or from the prodromal to the clinical phase
may not always be linear (Siderowf and Stern, 2008; Maetzler and
Hausdorff, 2012), we included parameters in our (second) model,
which have been shown to be altered in HRPD (but not in PD,
compared to CO) in a previous study investigating static sway
under challenging conditions.
Fourth, the particular experimental setting has not been val-
idated yet. However, Mancini et al. (2012) have shown in early
PD patients and healthy older adults that trunk accelerometry
parameters during quiet stance are strongly associated with bal-
ance platform parameters. Thus, experiments with accelerometry-
based quantitative sensors are a useful approach for measuring
parameters at (or nearby) the center of mass during quiet stance
(e.g., Moe-Nilssen and Helbostad, 2002; Lamoth et al., 2009; Lin-
demann et al., 2012). As our approach is basically comparable
to a quiet stance experiment, we argue that the quantitative data
obtained in this experiment reflects a kind of sway behavior during
quiet standing. However, a direct validation experiment has not
been performed. Fifth, the FR test itself faces some limitations:
it is not related to center of mass (CoM) or center of pressure
(CoP) limits of stability. It is performed only in one direction and
does not allow an identification of the type of balance problem
(Mancini and Horak, 2010). Still it has been associated with center
of pressure excursion (COPE), and is related to the margins of
stability and a functional assessment of an essential everyday life
task (Duncan et al., 1990).
CONCLUSION
The approach presented here does not definitely allow differenti-
ating between degeneration and compensation aspects of balance
at the limit of stability in PD and HRPD. Still, we believe that it
can relevantly contribute to an assessment panel for definition of
HRPD in future studies. In combination with tasks that assess
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other motor as well as non-motor domains of the PD spec-
trum, the iFR could serve as an important contribution to an
assessment battery that yields an acceptable positive predictive
value for future PD.
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